Volume 28, Number 10—October 2022
Research Letter
Sindbis Virus Antibody Seroprevalence in Central Plateau Populations, South Africa
Nicole Kennedy, Dominique Goedhals, Sabeehah Vawda, Philip Armand Bester, and Felicity Burt
Table
Sindbis virus–specific IgG and neutralizing antibodies in patient serum samples in study of Sindbis virus antibody seroprevalence in central plateau populations, South Africa*
| Patient group | Collection period, y | Patient samples |
|||
|---|---|---|---|---|---|
| No. IgG+/no. tested per group (%) | % IgG+ of total tested | No. IgG+/total IgG+ (%) | No. NA+/no. IgG+ tested | ||
| Patients attending rheumatology clinic | 2013–2017 | 31/165 (18.8) | 5.5 | 31/69 (44.9) | 29/31 |
| High-risk populations† | 2016–2017 | 13/136 (9.6) | 2.3 | 13/69 (18.8) | 13/13 |
| Patients with AFI, no diagnosis |
2007– 2010 |
25/267 (9.4) |
4.4 |
25/69 (36.2) |
23/25 |
| Total no. patients | 69/568 | 12.2 | 65/69 | ||
*We used an in-house ELISA to measure Sindbis virus–specific IgG and a 50% tissue culture infectious dose serum neutralization assay to measure Sindbis virus neutralizing antibodies in patient serum samples. AFI, acute febrile illness; NA, neutralizing antibody; +, positive. †Residents of Sindbis virus-endemic regions.
Page created: August 16, 2022
Page updated: September 21, 2022
Page reviewed: September 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.